Sea Limited stock soars to 52-week high of $126.43 amid robust growth

Published 11/02/2025, 16:50
Sea Limited stock soars to 52-week high of $126.43 amid robust growth

In a remarkable display of resilience and growth, Sea Limited (NYSE:SE)’s stock has surged to a 52-week high, reaching a price level of $126.43 USD. According to InvestingPro data, the company now commands a market capitalization of approximately $72 billion, with current trading levels suggesting the stock is slightly overvalued compared to its Fair Value. This significant milestone underscores the company’s strong performance over the past year, which is further highlighted by an impressive 1-year change of 189.07%. The company’s financial health is rated as "GOOD" by InvestingPro, with particularly strong momentum scores and solid revenue growth of 20% over the last twelve months. Investors have shown increased confidence in Sea Limited’s business model and future prospects, propelling the stock to new heights and reflecting a robust recovery from any previous lows. The company’s strategic initiatives and expansion into new markets are likely contributing factors to this upward trajectory, signaling a positive outlook for Sea Limited’s continued success in the competitive tech landscape. InvestingPro subscribers can access 18 additional investment tips and a comprehensive Pro Research Report for deeper insights into SE’s valuation and growth prospects.

In other recent news, Sea Ltd has been the subject of several analyst reports. Bernstein maintained an Outperform rating on the company’s stock, with a price target of $130, emphasizing the company’s strategic use of discounting to fuel growth and the expected quarterly strengthening of EBITDA. Similarly, BofA Securities maintained a Buy rating on Sea Ltd, with a price target of $134, highlighting the significant contribution of the game Free Fire to Garena’s EBITDA and the company’s efforts to diversify its gaming portfolio.

On a different note, Serina Therapeutics, Inc. expanded its Equity Incentive Plan, increasing the number of shares reserved for issuance under the plan by 950,000 shares. The pharmaceutical company also approved an automatic annual increase of 5% of the outstanding common stock starting with the 2026 fiscal year.

In more recent developments, Morgan Stanley (NYSE:MS) reiterated an Overweight rating on Sea Ltd’s stock, with a price target of $140. The firm’s analysis underlined the robust performance of Sea’s digital entertainment segment, particularly the game Free Fire, which saw a year-over-year revenue increase of 36%.

These recent updates highlight the ongoing strategic efforts of both Sea Ltd and Serina Therapeutics, as well as the positive outlook held by multiple analyst firms towards Sea Ltd.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.